Mymetics, RSV, Astellas, RRD International deal

Astellas and RRD International's ClearPath Development Co. subsidiary partnered to form a portfolio of asset-centric companies focused on vaccines for infectious diseases. ClearPath will house and manage each newco and will provide development expertise. Astellas will have an exclusive option to acquire the companies. RRD is a product development company for biotechs and pharmas. The partners declined to disclose additional details. ...